**Symposium Cochairs:**
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA
Riccardo Dalla-Favera, Columbia University, New York, NY

**MONDAY, MARCH 4**

**Registration**
3-8 P.M. | Essex Ballroom Foyer

**Welcome and Opening Keynote**
5-6 P.M. | Essex Ballroom South

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 5-5:10 | Welcome  
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA |
| 5:10-5:15 | Introduction of Keynote Speaker  
Riccardo Dalla-Favera, Columbia University, New York, NY |
| 5:15-5:45 | A new human hematopoietic stem cell that retains memory of prior inflammatory stresses links inflammation, aging, CH and pre-leukemia initiation  
John E. Dick, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada |
| 5:45-6 | Q&A |

**Plenary Session 1: Genetic Predisposition**
6-8:05 P.M. | Essex Ballroom South  
*Session Chair: Jennifer R. Brown, Dana-Farber Cancer Institute, Boston, MA*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 6-6:05 | Introduction  
Jennifer R. Brown |
| 6:05-6:25 | The new genomics of T-lineage acute lymphoblastic leukemia  
Charles G. Mullighan, St. Jude Children’s Research Hospital, Memphis, TN |
| 6:25-6:35 | Q&A |
| 6:35-6:55 | Germline predisposition to Chronic Lymphocytic Leukemia  
Jennifer R. Brown |
| 6:55-7:05 | Q&A |
| 7:05-7:15 | Impact of germline and somatic ATM variants in Chronic Lymphocytic Leukemia (CLL): Clinical implications and response to PARP inhibition*  
Kiyomi Mashima, Dana-Farber Cancer Institute, Boston, MA |
| 7:15-7:20 | Q&A |

* - short-talk from proffered paper
7:20-7:40 Genetic determinants of racial disparities in multiple myeloma
Francesco Maura, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL

7:40-7:50 Q&A

7:50-8:05 Panel Discussion

Opening Reception
8:05-10 P.M. | Essex Ballroom Center

TUESDAY, MARCH 5

Breakfast / Meet-the-BCD-Editors
7-8 A.M. | Essex Ballroom North

Plenary Session 2: Somatic Genomic Lesions
8-9:50 A.M. | Essex Ballroom South
Session Chair: Laura Pasqualucci, Columbia University, New York, NY

CME Eligible

8-8:05 Introduction
Laura Pasqualucci

8:05-8:25 Invariant somatic mutations identify distinct subgroups of multiple myeloma
P. Leif Bergsagel, Mayo Clinic Arizona, Scottsdale, AZ
8:25-8:35 Q&A

8:35-8:55 Genetics-driven dysregulation of super enhancer networks in Diffuse Large B-cell Lymphoma
Laura Pasqualucci
8:55-9:05 Q&A

9:05-9:25 Somatic mutations in peripheral T-cell lymphoma: Lineage specification and microenvironment remodeling
Teresa Palomero, Columbia University, New York, NY
9:25-9:35 Q&A

9:35-9:50 Panel Discussion

Break
9:50-10:10 A.M. | Essex Ballroom Foyer

* - short-talk from proffered paper
Plenary Session 3: Precursor Conditions
10:10 A.M.-12 P.M. | Essex Ballroom South
Session Chair: Ross L. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY

10:10-10:15  Introduction
Ross L. Levine

10:15-10:35  Deciphering and targeting clonal hematopoiesis
Ross L. Levine
10:35-10:45  Q&A

10:45-11:05  The promise of early detection and interception of multiple myeloma
Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, MA
11:05-11:15  Q&A

11:15-11:35  Genetic and epigenetic evolution of Follicular Lymphoma precursors and their transformation
Ash A. Alizadeh, Stanford University, Stanford, CA
11:35-11:45  Q&A

11:45-12  Panel Discussion
Lunch on own / Free time
12-2 P.M.

(DO NOT DISPLAY ON WEB - may want to do editorial board retreat at lunch, 25 max)

Plenary Session 4: Tumor Microenvironment
2-3:50 P.M. | Essex Ballroom South
Session Chair: Madhav V. Dhodapkar, Emory University, Atlanta, GA

2-2:05  Introduction
Madhav V. Dhodapkar

2:05-2:25  Follicular lymphoma tumor microenvironment: T cell-stroma interactions at the front
Karin Tarte, University of Rennes, Rennes, France
2:25-2:35  Q&A

2:35-2:55  Regulation of immune microenvironment in plasma cell tumors
Madhav V. Dhodapkar
2:55-3:05  Q&A

* - short-talk from proffered paper
3:05-3:25  Regulation of T cell interactions in myeloid leukemia  
Iannis Aifantis, New York University Langone Health, New York, NY

3:25-3:35  Q&A

3:35-3:50  Panel Discussion

Break
3:50-4:10 P.M. | Essex Ballroom Foyer

**Plenary Session 5: Epigenetic Pathways**

4:10-6:30 P.M. | Essex Ballroom South

*Session Chair: Ari M. Melnick, Weill Cornell Medicine, New York, NY*

4:10-4:15  Introduction  
Ari M. Melnick

4:15-4:35  Epigenetic mechanisms and therapy of B cell lymphomas  
Ari M. Melnick

4:35-4:45  Q&A

4:45-4:55  ARID1A mutations shape memory B-cell dynamics and confer sensitivity to SWI/SNF remodeling complex inhibition in lymphoma  
Darko Barisic, Weill Cornell Medicine, New York, NY

4:55-5:00  Q&A

5:00-5:20  Mitochondrial and metabolic pathways in AML: Biological insights and new therapeutic targets  
Aaron D. Schimmer, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada

5:20-5:30  Q&A

5:30-5:40  Decoding cancer dependency and molecular pathways of long noncoding RNAs with a novel CRISPR-Cas13d platform  
Eugenio Morelli, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy

5:40-5:45  Q&A

5:45-6:05  Separating and uniting genetic and cellular hierarchies in myeloid leukemia  
Eirini Papapetrou, Icahn School of Medicine at Mount Sinai, New York, NY

6:05-6:15  Q&A

6:15-6:30  Panel Discussion

**Poster Session and Reception**

6:30-8:30 P.M. | Essex Ballroom North

* - *short-talk from proffered paper*
WEDNESDAY, MARCH 6

Breakfast
7-8 A.M. | Essex Ballroom North

Keynote Lecture
8-8:50 A.M. | Essex Ballroom South
Session Chair: Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA

8-8:05 Introduction of Keynote Speaker
Kenneth C. Anderson

8:05-8:35 Novel paradigms for drug development in hematologic malignancies
Nicole J. Gormley, U.S. Food and Drug Administration Center for Drug Evaluation and Research, Silver Spring, MD

8:35-8:50 Q&A

Break
8:50-9 A.M. | Essex Ballroom Foyer

Plenary Session 6: Molecular Diagnosis and Prognosis
9-11:05 A.M. | Essex Ballroom South
Session Chair: Anthony G. Letai, Dana-Farber Cancer Institute, Boston, MA

9-9:05 Introduction
Anthony G. Letai

9:05-9:25 Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia
Anthony G. Letai

9:25-9:35 Q&A

9:35-9:45 Leveraging probabilistic causal disease models to understand molecular pathways and target resistance mechanisms in Multiple Myeloma with the CREBBP and EP300 bromodomain inhibitor, pocenbrodib
Allison Roder, Pathos AI, Salt Lake City, UT

9:45-9:50 Q&A

9:50-10:10 Kinetics and biology of CTCs and MRD: Two dynamic high-risk clones in multiple

* - short-talk from proffered paper
Blood Cancer Discovery Symposium
March 4-6, 2024 | Westin Copley Place | Boston, MA

* - short-talk from proffered paper

10:10-10:20 Q&A

10:20-10:40 Exploring Classic Hodgkin Lymphoma Genetics through Liquid Biopsy
Davide Rossi, Institute of Oncology Research, Bellinzona, Switzerland

10:40-10:50 Q&A

10:50-11:05 Panel Discussion

Break
11:05-11:20 A.M. | Essex Ballroom Foyer

Plenary Session 7: Immune Therapy and Escape
Session Chair: Eric L. Smith, Dana-Farber Cancer Institute, Boston, MA

11:20-11:25 Introduction
Eric L. Smith

11:25-11:45 Molecular determinants of response and resistance to lymphoma immunotherapy
Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA

11:45-11:55 Q&A

11:55-12:05 RH0A inactivation subverts IFN-γ response and promotes antigen escape in CAR-T resistant diffuse large B-cell lymphoma
Austin Newsam, University of Miami Miller School of Medicine, Miami, FL

12:05-12:10 Q&A

12:10-12:30 Novel CAR targets for hematologic malignancies
Marcela V. Maus, Massachusetts General Hospital, Boston, MA

12:30-12:40 Q&A

12:40-12:50 GABARAP deficiency drives resistance to immunogenic chemotherapy in multiple myeloma
Marcello Turi, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy

12:50-12:55 Q&A

12:55-1:15 Addressing mechanisms of resistance to T cell redirection immunotherapies for multiple myeloma
Eric L. Smith

1:15-1:25 Q&A

Lunch (provided)
1:25-1:45 P.M. | Essex Ballroom Foyer
Plenary Session 8: Precision Medicine
1:45-3:50 P.M. | Essex Ballroom South
Session Chair: Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA

1:45-1:50 Introduction
Kenneth C. Anderson

1:50-2:10 Curing aggressive lymphomas with aggressive combinations of drugs targeting oncogenic mechanisms
Louis M. Staudt, National Cancer Institute, Bethesda, MD
2:10-2:20 Q&A

2:20-2:30 Zotatifin, the eukaryotic translation initiation factor 4A (eIF4A) inhibitor, synergizes with Venetoclax to inhibit acute myeloid leukemia cell growth
Yoke Seng Lee, Harvard Medical School/Brigham and Women’s Hospital, Boston, MA
2:30-2:35 Q&A

2:35-2:55 Is there a role for precision medicine in multiple myeloma?
Faith E. Davies, New York University Langone Health Perlmutter Cancer Center, New York, NY
2:55-3:05 Q&A

3:05-3:15 Altered RNA export sensitizes to nuclear export inhibition in SF3B1 mutant MDS
Sana Chaudhry, University of Miami Miller School of Medicine, Miami, FL
3:15-3:20 Q&A

3:20-3:40 Targeted protein degradation for the treatment of hematologic malignancies
Benjamin L. Ebert, Dana-Farber Cancer Institute, Boston, MA
3:40-3:50 Q&A

Closing Comments and Departure
3:50-4 P.M. | Essex Ballroom South
Riccardo Dalla-Favera, Columbia University, New York, NY

* - short-talk from proffered paper